# MEN2312 in advanced breast cancer

Source: https://onco.cc/trials/nct06638307/  
OnCo record `nct06638307` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This first human study tests MEN2312, a drug that blocks an enzyme involved in controlling gene activity. It studies safety, dose and early signs of activity in advanced breast cancer.

## Summary

This first human study tests MEN2312, a drug that blocks an enzyme involved in controlling gene activity. It studies safety, dose and early signs of activity in advanced breast cancer.

Interventional study registered as NCT06638307, sponsored by Stemline Therapeutics, Inc.. Registry phase: 1. Registry enrollment is 240 participants (estimated). Registry status checked October 10, 2026: recruiting. UCSF lists this study as open to eligible people; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-10
- Also known as: A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- Tags: ucsf-breast-coverage; interventional
- Registry id: NCT06638307
- Phase: 1
- Setting: Advanced breast cancer
- Sponsor: Stemline Therapeutics, Inc.

## Sources

- ClinicalTrials.gov NCT06638307: https://clinicaltrials.gov/study/NCT06638307
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT06638307

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Elacestrant](https://onco.cc/drugs/elacestrant/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct06638307.json